For release: 4 June 2018
genedrive plc ("genedrive" or the "Company")
Result of General Meeting
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that at the General Meeting, held at The Innovation Centre, 48 Grafton Street, Manchester, M13 9XX today, the resolution proposed was duly passed. Following this approval, the disposal of the Group's contract research and pharmacogenomics divisions is expected to complete within the next 10 days.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Stanford Capital Partners Limited +44 (0)203 815 8880
Patrick Claridge
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.
Further details can be found at: www.genedriveplc.com and www.genedrive.com